Resource title

The national regulation of pharmaceutical markets and the timing of new drug launches in Europe

Resource image

image for OpenScout resource :: The national regulation of pharmaceutical markets and the timing of new drug launches in Europe

Resource description

We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA's centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when investigating the impact of indirect price controls. Our results show that Germany (65%) has the highest probability of experiencing an early launch, while it is the lowest in southern European countries (18% for Portugal and 19% for Greece). This difference accrues from both price regulation and market attractiveness, since southern European countries generally have lower prices. Due to the possibilities for parallel trade within the EU, pharmaceutical companies, by acting strategically, may further increase launch delays.

Resource author

Alexander Heuer, Malwina Mejer, Jennifer Neuhaus

Resource publisher

Resource publish date

Resource language

eng

Resource content type

text/html

Resource resource URL

http://hdl.handle.net/10419/27014

Resource license

Adapt according to the presented license agreement and reference the original author.